Pelgraz, sol inj 6 mg/0.6 ml sécurisée , ser pré 0.6 ml (ancien)
7680674050018
CH-67405
L03AA13
Reimbursement limitations:
NEULASTA
Administration au cours des chimiothérapies fortement myélotoxiques permettant d'espérer une évolution positive chez les patients …
1 / 3
google
Details
- Product number
- -
- CPT
- -
- Packaging group
- -
- Unit
- -
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
6.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
30.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
0.019 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 1105.85
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/11/2019
Authorization holder
Accord Healthcare AG
4103 Bottmingen
Authorization information
- Swissmedic authorization number
- 67405
- Drug name
- Pelgraz, Injektionslösung in einer Fertigspritze
- Galenic form
- INLFS
- ATC Code
- L03AA13
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 29/08/2019
- Authorization expiration date
- 31/12/9999
- IT number
- 06.07.3.
- Domain
- Human medicine
Packaging details
- Description (FR)
- PELGRAZ 6 mg/0.6ml seringue pré sécurisée 0.6 ml
- Description (DE)
- PELGRAZ 6 mg/0.6ml Fertigspr m Nadelschutz 0.6 ml
- Narcotic (BTM)
- No